The 6% Mo Superaustenitics, the Cost Effective Alternative to Nickel Alloys

1993 ◽  
Vol 11 (3-4) ◽  
pp. 65-82
Author(s):  
D.C. Agarwal, ◽  
F.E. White, ◽  
W.R. Herda,
2020 ◽  
Vol 182 (2) ◽  
pp. C5-C7
Author(s):  
Warrick J Inder

While the ACTH1–24 test has some well-documented shortcomings, it is the most widely used test to diagnose primary and secondary adrenal insufficiency. However, this synthetic ACTH preparation is not readily available in some countries. Research from India has demonstrated that using a long-acting porcine sequence ACTH has similar diagnostic performance to ACTH1–24 at around 25% of the cost. This may allow access to a robust test for adrenal insufficiency to developing countries and potentially allow thousands of patients to be identified and appropriately treated.


2011 ◽  
Vol 19 (3) ◽  
pp. 474-483 ◽  
Author(s):  
R Ara ◽  
A Pandor ◽  
J Stevens ◽  
R Rafia ◽  
SE Ward ◽  
...  

Background: While evidence shows high-dose statins reduce cardiovascular events compared with moderate doses in individuals with acute coronary syndrome (ACS), many primary care trusts (PCT) advocate the use of generic simvastatin 40 mg/day for these patients. Methods and results: Data from 28 RCTs were synthesized using a mixed treatment comparison model. A Markov model was used to evaluate the cost-effectiveness of treatments taking into account adherence and the likely reduction in cost for atorvastatin when the patent expires. There is a clear dose–response: rosuvastatin 40 mg/day produces the greatest reduction in low-density lipoprotein cholesterol (56%) followed by atorvastatin 80 mg/day (52%), and simvastatin 40 mg/day (37%). Using a threshold of £20,000 per QALY, if adherence levels in general practice are similar to those observed in RCTs, all three higher dose statins would be considered cost-effective compared to simvastatin 40 mg/day. Using the net benefits of the treatments, rosuvastatin 40 mg/day is estimated to be the most cost-effective alternative. If the cost of atorvastatin reduces in line with that observed for simvastatin, atorvastatin 80 mg/day is estimated to be the most cost-effective alternative. Conclusion: Our analyses show that current PCT policies intended to minimize primary care drug acquisition costs result in suboptimal care.


Author(s):  
P N Johnson

Feeding pregnant ewes on silage-based rations during housing is widely practised. However, silage making is a capital intensive procedure and the cost is likely to increase due to pollution legislation. Feeding ewes on a cereal-based ration may be a cost effective alternative. This is especially relevant due to the ban on straw burning and the possibility of CAP reform forcing cereal prices down. This experiment compares the effect of silage- and wheat-based rations during the winter housing period on ewe and lamb performance.Approximately 260 mule (Bluefaced Leicester x Swaledale) ewes were selected from the breeding flock at the time of winter housing in January 1989, 1990 and 1991. They had previously been at grass and had run with Suffolk rams between mid-October and mid-December.


Mathematics ◽  
2021 ◽  
Vol 9 (18) ◽  
pp. 2331
Author(s):  
Marta Osca-Guadalajara ◽  
Javier Díaz-Carnicero ◽  
Silvia González-de-Julián ◽  
David Vivas-Consuelo

Osteoporosis is frequent in elderly people, causing bone fractures and lowering their quality of life. The costs incurred by these fractures constitute a problem for public health. Markov chains were used to carry out an incremental cost-utility analysis of the four main drugs used in Spain to treat osteoporosis (alendronate, risedronate, denosumab and teriparatide). We considered 14 clinical transition states, from starting osteoporotic treatment at the age of 50 until death or the age of 100. Cost-effectiveness was measured by quality adjusted life years (QALYs). The values used in the Markov model were obtained from the literature. Teriparatide is the cost-effective alternative in the treatment of osteoporosis in patients with fractures from the age of 50, establishing a payment threshold of 20,000 EUR/QALY. However, it is the most expensive therapy, not appearing cost-effective in cases that do not present fracture and in ages over 80 years with fracture. Alendronate and denosumab therapies are presented as cost-effective osteoporosis treatment alternatives depending on the age of onset and duration of treatment. From the perspective of cost-effectiveness, establishing a payment threshold of 20,000 EUR/QALY, teriparatide is the cost-effective alternative in patients with fracture from the age of 50 to 70 years old in Spain.


Author(s):  
Sankara Raman ◽  
Margaret J. Rys ◽  
Eugene R. Russell

There is a wealth of information related to life-cycle costs of different sign sheeting materials and considerable information on common signposts, but there is little or no information about the life-cycle costs of different types of signposts. The primary objective of this research was to determine the best cost-effective policy, consistent with safety, for signpost materials and types used on state highways in Kansas. From the initial literature review, a matrix was constructed detailing the various materials used for signposts by each state. This was followed with a survey questionnaire to gather information on what posts other states were using for three major types of signs used in Kansas. From the data obtained from the state departments of transportation, test installations were carried out by three vendors. Life-cycle economic analysis was conducted, taking into consideration the labor, equipment, and time requirements for the initial installation and the replacement. Among the four systems compared for a single signpost, the Poz-Loc Socket System is the most cost-effective alternative in life-cycle costs, followed by the Break-Out Sign Support System, the 4″ x 4″ x 14′ wood post, and the Telespar anchor-driven unit. Among the three systems compared for a double signpost, the Poz-Loc Slipbase System is the most cost-effective alternative, followed by the Telespar Slipbase System, and the double 4″ x 6″ x 16′ wood post. The present worth analysis and sensitivity analysis, conducted according to varying the interest rate, did not have any significant effect in changing the cost-effective alternative.


Alloy Digest ◽  
2009 ◽  
Vol 58 (11) ◽  

Abstract Ancorsteel 4300 alloy ferrous powder simulates wrought steel compositions and is a cost-effective alternative to alloys requiring secondary processing. This datasheet provides information on composition, physical properties, hardness, and tensile properties as well as fracture toughness. It also includes information on heat treating and powder metal forms. Filing Code: SA-611. Producer or source: Hoeganaes Corporation.


2021 ◽  
Vol 80 (Suppl 1) ◽  
pp. 119-120
Author(s):  
N. Østerås ◽  
E. Aas ◽  
T. Moseng ◽  
L. Van Bodegom-Vos ◽  
K. Dziedzic ◽  
...  

Background:To improve quality of care for patients with hip and knee osteoarthritis (OA), a structured model for integrated OA care was developed based on international treatment recommendations. A previous analysis of a cluster RCT (cRCT) showed that compared to usual care, the intervention group reported higher quality of care and greater satisfaction with care. Also, more patients were treated according to international guidelines and fulfilled recommendations for physical activity at the 6-month follow-up.Objectives:To assess the cost-utility of a structured model for hip or knee OA care.Methods:A cRCT with stepped-wedge cohort design was conducted in 6 Norwegian municipalities (clusters) in 2015-17. The OA care model was implemented in one cluster at the time by switching from “usual care” to the structured model. The implementation of the model was facilitated by interactive workshops for general practitioners (GPs) and physiotherapists (PTs) with an update on OA treatment recommendations. The GPs explained the OA diagnosis and treatment alternatives, provided pharmacological treatment when appropriate, and suggested referral to physiotherapy. The PT-led patient OA education programme was group-based and lasted 3 hours followed by an 8–12-week individually tailored resistance exercise programme with twice weekly 1-hour supervised group sessions (5–10 patients per PT). An optional 10-hours Healthy Eating Program was available. Participants were ≥45 years with symptomatic hip or knee OA.Costs were measured from the healthcare perspective and collected from several sources. Patients self-reported visits in primary healthcare at 3, 6, 9 and 12 months. Secondary healthcare visits and joint surgery data were extracted from the Norwegian Patient Register. The health outcome, quality-adjusted life-year (QALY), was estimated based on the EQ-5D-5L scores at baseline, 3, 6, 9 and 12 months. The result of the cost-utility analysis was reported using the incremental cost-effectiveness ratio (ICER), defined as the incremental costs relative to incremental QALYs (QALYs gained). Based on Norwegian guidelines, the threshold is €27500. Sensitivity analyses were performed using bootstrapping to assess the robustness of reported results and presented in a cost-effectiveness plane (Figure 1).Results:The 393 patients’ mean age was 63 years (SD 9.6) and 74% were women. 109 patients were recruited during control periods (control group), and 284 patients were recruited during interventions periods (intervention group). Only the intervention group had a significant increase in EQ-5D-5L utility scores from baseline to 12 months follow-up (mean change 0.03; 95% CI 0.01, 0.05) with QALYs gained: 0.02 (95% CI -0.08, 0.12). The structured OA model cost approx. €301 p.p. with an additional €50 for the Healthy Eating Program. Total 12 months healthcare cost p.p. was €1281 in the intervention and €3147 in the control group, resulting in an incremental cost of -€1866 (95% CI -3147, -584) p.p. Costs related to surgical procedures had the largest impact on total healthcare costs in both groups. During the 12-months follow-up period, 5% (n=14) in the intervention compared to 12% (n=13) in the control group underwent joint surgery; resulting in a mean surgical procedure cost of €553 p.p. in the intervention as compared to €1624 p.p. in the control group. The ICER was -€93300, indicating that the OA care model resulted in QALYs gained and cost-savings. At a threshold of €27500, it is 99% likely that the OA care model is a cost-effective alternative.Conclusion:The results of the cost-utility analysis show that implementing a structured model for OA care in primary healthcare based on international guidelines is highly likely a cost-effective alternative compared to usual care for people with hip and knee OA. More studies are needed to confirm this finding, but this study results indicate that implementing structured OA care models in primary healthcare may be beneficial for the individual as well as for the society.Disclosure of Interests:None declared


Sign in / Sign up

Export Citation Format

Share Document